Biogen, Mirimus Team Up For RNAi-Based Therapeutics For Neurological Indications

  • Mirimus Inc has collaborated with Biogen Inc BIIB to develop RNAi-based therapeutics targeting multiple, undisclosed neurological disease indications. 
  • Terms of the collaboration are not disclosed.
  • Under the agreement, Mirimus will engineer RNAi-based therapeutics that Biogen will assess to determine feasibility in potential neurological disease settings. 
  • If feasibility is established, the companies will have the option to pursue pre-clinical development of the asset(s).
  • Price Action: BIIB shares are down 0.75% at $320.06 during the market session on the last check Wednesday.
Loading...
Loading...
BIIB Logo
BIIBBiogen Inc
$129.79-2.23%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
18.52
Growth
41.42
Quality
17.64
Value
29.57
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Comments
Loading...